Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether low-dose colchicine, an anti-inflammatory drug, can reduce the risk of serious vascular events in patients with symptomatic peripheral artery disease PAD. This study is a randomized, double-blind, multicenter trial involving 6,150 participants, aiming to prevent events such as heart attack, stroke, cardiovascular death, severe limb ischemia, and major vascular amputation. The primary outcome measured is a combination of major adverse cardiovascular and limb events MACE and MALE. Participants are randomly assigned to receive either colchicine 0.5 mg once daily or a placebo that looks identical. The trial includes an active run-in period and will continue over a period of 3 to 5 years, during which patients take their assigned tablets daily. Both the active drug and placebo are stored securely and administered under blinded conditions so neither patients nor investigators know which treatment is given. Throughout the study, participants will be regularly monitored for cardiovascular events and limb health. Evaluations include tracking occurrences of heart attacks, strokes, hospitalization, vascular interventions, amputations, and mortality. Quality of life and physical activity are also assessed using specific questionnaires. Safety monitoring and follow-up will continue for the duration of the trial, which may last up to 5 years for each participant.